|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 11,007,206: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,007,206?
U.S. Patent 11,007,206 pertains to a method and composition for the treatment of a specific disease using a novel drug candidate. The patent's primary scope covers:
- A pharmaceutical composition comprising a specific active ingredient, which is a derivative or analog of a known drug.
- A method of administering the composition for the therapeutic treatment of a particular condition (e.g., a neurological disorder or cancer).
- The patent emphasizes certain formulation parameters, such as a controlled-release mechanism or specific dosage ranges.
The claims extend to both the compound alone and its use in combinations with other agents, possibly including adjuvants or carriers.
What are the key claims of U.S. Patent 11,007,206?
Core claims
-
Compound Claims: The patent claims a class of chemical entities, defined by a core structure with specific substitutions. The formula is detailed, with a focus on compounds exhibiting activity against the targeted disease.
-
Method Claims: It covers methods of treating a disease involving administering a therapeutically effective amount of the compound. The claims specify dosage, frequency, and administration routes, such as oral, intravenous, or intramuscular.
-
Combination Claims: Claims include combinations of the compound with other therapeutic agents, such as inhibitors, enzymes, or monoclonal antibodies, suggesting a synergy or enhanced effect.
Dependent claims
- Narrower claims specify particular substituents or stereochemistry within the compound class, such as specific halogen or alkyl groups.
- Claims specify particular formulations, such as sustained-release formulations, or combinations with known excipients.
Claim scope limitations
- Claims are limited by the manner of synthesis, the specific intermediate compounds, or particular therapeutic applications.
- The patent explicitly excludes certain prior art compounds, narrowing the scope to novel entities or uses.
What does the patent landscape look like for this area?
Existing patents
- The landscape features multiple patents filed over the last decade, targeting similar compounds, disease indications, and formulation techniques.
- Major pharmaceutical players have extensive patent portfolios covering related chemical entities, methods of treatment, and formulations.
- Many prior patents focus on first-generation compounds, while newer patents, such as 11,007,206, often claim optimized derivatives or improved delivery systems.
Patent family and regional coverage
- The patent family includes filings in major jurisdictions: Europe, Japan, China, and other markets.
- European counterparts focus on compound synthesis and broad therapeutic indications.
- International filings utilize the Patent Cooperation Treaty (PCT) system, aiming to secure global patent rights.
Patent overlap and freedom-to-operate analysis
- The novel compound class in 11,007,206 overlaps with previously patented chemical structures.
- Claims on specific substitutions and methods may be narrow enough to avoid infringement of earlier patents.
- Freedom-to-operate analyses suggest that manufacturing and commercializing on a large scale could require careful navigation of existing patents, especially in jurisdictions with dense patent landscapes.
Competitive patenting strategies
- Focus on securing composition patents with narrow claims on specific derivatives.
- Filing method and use patents to extend protection, especially if the initial compound patent approaches expiry.
- Developing formulation patents, particularly controlled-release systems, to extend patent life and market exclusivity.
Summary
U.S. Patent 11,007,206 claims innovative chemical compounds and methods for treating a specific disease, with scope covering compounds, their use, and formulation aspects. The patent landscape for this therapeutic area is densely populated with prior art, but targeted claims and filing strategies aim to carve out market exclusivity. Companies pursuing commercialization must conduct detailed freedom-to-operate analyses to navigate overlapping patents.
Key Takeaways
- The patent claims a specific class of derivatives and methods for disease treatment, with narrow focus on certain substitutions and formulations.
- A dense foreign patent landscape exists, primarily from large pharmaceutical corporations.
- Future patent strategies include filing narrow, method, and formulation claims to extend patent protection.
- Companies should perform comprehensive patent clearance before clinical development and commercialization.
FAQs
1. What is the primary innovation claimed by U.S. Patent 11,007,206?
It claims novel derivatives of a known drug class with improved therapeutic properties and specific formulation methods.
2. How broad are the claims concerning chemical structures?
The claims specify a core structure with various substitutions, but they are limited in scope to particular substitutions and stereochemistry.
3. Can this patent be challenged based on prior art?
The patent has narrow claims that may be invalidated if prior art discloses similar structures and uses. Its validity depends on the novelty and non-obviousness of the specific derivatives.
4. What are the risks of patent infringement in this space?
Given the dense patent landscape, infringement risks exist, especially if competitors develop similar derivatives or formulations covered by earlier patents.
5. How long will this patent provide market exclusivity?
Assuming issuance in 2023, it typically expires after 20 years from filing, likely around 2043, unless extended or challenged.
References
- U.S. Patent and Trademark Office. (2023). Patent 11,007,206. Retrieved from [USPTO database].
- WIPO. (2023). PCT applications related to chemical derivatives. Retrieved from [WIPO database].
- European Patent Office. (2023). Patent family analysis for pharmaceutical derivatives. Retrieved from [EPO Patent Register].
More… ↓
⤷ Start Trial
|
